Risk-benefit considerations in the management of polymyalgia rheumatica.
Management of the polymyalgia rheumatica syndrome (PMR) is controversial. Gratifying symptomatic response usually occurs after treatment with nonsteroidal antiinflammatory drugs or low doses of corticosteroids. However, some PMR patients are at risk of sudden blindness from an associated disease, giant cell arteritis (GCA). Blindness can be prevented by using higher and more toxic doses of corticosteroids. Temporal artery biopsy can be an aid in diagnosis, though it is not a completely sensitive test for GCA. This study employs decision analysis and derived risk-benefit ratios (equivalent to utility ratios) to evaluate five possible PMR management strategies. The incremental risk-benefit analysis provides a means for weighing intangible trade-offs without a formal utility analysis. Given base case assumptions derived from the literature, empirical treatment with high-dose steroids cannot be justified for PMR patients who have no cranial arteritic symptoms, because the acceptable risk-benefit ratio associated with this strategy is more than 90 cases of severe medication side effects per case of monocular blindness averted.
D000305:Adrenal Cortex Hormones / Q000009:adverse effects / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001706:Biopsy; D001766:Blindness / Q000209:etiology; D013700:Giant Cell Arteritis / Q000150:complications* / Q000175:diagnosis; D006801:Humans; D011111:Polymyalgia Rheumatica / Q000150:complications / Q000188:drug therapy*; D012306:Risk
D000305:Adrenal Cortex Hormones; D000893:Anti-Inflammatory Agents